J Med Microbiol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alcalá, B.
Right arrow Articles by Vázquez, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alcalá, B.
Right arrow Articles by Vázquez, J. A.
Agricola
Right arrow Articles by Alcalá, B.
Right arrow Articles by Vázquez, J. A.
J Med Microbiol 53 (2004), 515-518; DOI: 10.1099/jmm.0.05517-0
© 2004 Society for General Microbiology
ISSN 0022-2615

Antigenic and/or phase variation of PorA protein in non-subtypable Neisseria meningitidis strains isolated in Spain

Belen Alcalá, Celia Salcedo, Luisa Arreaza, Raquel Abad, Rocio Enríquez, Laura De La Fuente, Maria Jose Uría and Julio A. Vázquez

Reference Laboratory for Neisseria, National Center of Microbiology, Institute of Health Carlos III, Ctra. Majadahonda-Pozuelo Km2, 28220 Majadahonda, Madrid, Spain

Correspondence Julio A. Vázquez jvazquez{at}isciii.es

Received October 23, 2003
Accepted February 4, 2004

The PorA protein is a potential candidate as a vaccine component against meningococcal disease. However, this protein experiences antigenic variation and is subject to phase variations to evade immune selective pressure. In this study, the mechanisms responsible for altered expression of the PorA protein were analysed in 50 non-subtypable strains isolated from patients with meningococcal disease in Spain. The porA gene was amplified from 47 of the 50 strains. The majority of isolates were not recognized by the subtyping panel, as a result of non-synonymous base changes in the variable regions of the porA gene. Two of these strains revealed a premature stop codon before the variable region VR1 of PorA due to a single base-pair substitution at position 109 of the porA coding region. Another two presented a homopolymeric tract of eight adenine residues in the coding region, producing a DNA strand-slippage mechanism and PorA phase variation.


Abbreviation: NST, non-subtypable.

The GenBank accession number for the sequence of porA from Neisseria meningitidis isolate 9688 is AY319969.


    INTRODUCTION
 TOP
 INTRODUCTION
 METHODS
 RESULTS AND DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
The major outer-membrane protein PorA of Neisseria meningitidis is the product of the porA gene, being expressed by most clinical isolates but with variation in the levels of expression (Hopman et al., 1994; van der Ende et al., 1995; Sawaya et al., 1999). Despite its antigenic variation, PorA is a potential component of N. meningitidis vaccines. Previous studies have shown that mAbs directed against serosubtype-specific epitopes on PorA have bactericidal activity in serum and confer protection against N. meningitidis infection in an animal model (Saukkonen et al., 1987, 1989). Moreover, immunization of volunteers with experimental vaccines based on outer-membrane vesicles demonstrated that bactericidal polyclonal antibodies are mainly directed against this protein, and the presence of these antibodies has been accepted as a marker for protection against infection caused by strains with the same serosubtype(s) as those of the vaccine strain (Rosenqvist et al., 1995; van der Voort et al., 1997; Longworth et al., 2002). During the past decade, single and multivalent vaccines composed of different PorA epitopes have been developed according to the most prevalent circulating serosubtypes in different geographical areas (Peeters et al., 1996; Cartwright et al., 1999; de Kleijn et al., 2000; Martin et al., 2001).

Because the serosubtype prevalence of meningococci changes over time, continuous monitoring of the circulating serosubtypes is necessary to adapt the vaccine composition in a particular region. Therefore, knowledge of the genetic mechanisms behind the variability of PorA expression is important for designing these kinds of vaccines.

However, previous studies showed that PorA expression could be altered by multiple mechanisms. Slipped-strand mispairing during replication in the homopolymeric tract of guanidine (polyG) and/or thymidine residues between the –10 and –35 domains of the porA promoter, as well as the homopolymeric tract of adenine (polyA) residues in the porA coding region are the principal mechanisms responsible for altered PorA expression (van der Ende et al., 1995, 2000; Sawaya et al., 1999). In addition, point mutations (Arhin et al., 1997; van der Ende et al., 2000, 2003) or insertion of an IS element (Newcombe et al., 1998) in the porA coding region or deletion of the complete porA gene (van der Ende et al., 1999) may result in meningococci lacking PorA expression.

In this study, 50 non-subtypable (NST) strains isolated from patients with meningococcal disease in Spain were analysed to identify the mechanisms responsible for altered expression of the PorA protein.


    METHODS
 TOP
 INTRODUCTION
 METHODS
 RESULTS AND DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
Bacterial strains and chromosomal DNA isolation.

Isolates were recovered from blood or cerebrospinal fluid of patients with meningococcal disease in Spain. They were serogrouped/serosubtyped as described previously (Vázquez et al., 1994). A total of 601 strains were characterized as NST by the Spanish Reference Laboratory for Meningococci between 1995 and 2000 using the available panel of mAbs in a whole-cell ELISA. Fifty (8.3 %) of those NST isolates were chosen randomly and included in our study.

For DNA extraction, samples were heated at 100 °C (20 min), subjected to one freeze–thaw cycle (2 min freezing) and then centrifuged for 5 min at 10 000 g.

Detection and sequencing of the porA gene by PCR.

Presence of the porA gene was analysed by PCR using primers P.210 and P.211 as described previously (Urwin, 2001). For full-length porA gene sequencing, a subset of eight oligonucleotides (including P.210 and P.211) was used (Urwin, 2001).

Outer-membrane protein analysis by SDS-PAGE.

Outer- membrane proteins were isolated and analysed by SDS-PAGE as described previously (Crowe et al., 1989). Protein content was determined by Bradford protein assay reagent (Bio-Rad). Ten micrograms of each isolate was loaded on 12 % polyacrylamide SDS gels. Protein profiles were visualized and images were captured and analysed using Quantity one software (Bio-Rad).

In some cases, to confirm the presence of PorA, proteins were transferred to nitrocellulose membrane by blotting. PorA was detected by adding the corresponding anti-PorA mAb at the appropriate dilution. Filters were washed and proteins visualized with the ECL chemiluminescent substrate system (Amersham Biosciences). Analysis of the images was performed using Quantity one software.

Detection and sequencing of the porA promoter region by PCR.

The porA promoter region was amplified and sequenced using PorA5 as forward primer (van der Ende et al., 1999) and P1-1 or 504 as reverse primers as described previously (Feavers & Maiden, 1998; van der Ende et al., 1999).

porA mRNA analysis by RT-PCR.

Expression of porA mRNA was monitored by RT-PCR. The 50 µl reaction mixture contained 250 ng total RNA (RNA was isolated using the Promega SV total RNA isolation system), 0.2 mM each dNTP, 1 mM MgSO4, 5 U AMV RT, 5 U Tfl DNA polymerase and 1 µM of the corresponding oligonucleotides. RNA was reverse-transcribed using oligonucleotide porA101, described previously by Deghmane et al. (2002), and amplification was then performed with oligonucleotides porA101 and porAO (Deghmane et al., 2002) resulting in an internal fragment of 170 bp. As an internal control, primers specific for the ctrA gene (Guiver & Borrow, 2001) were used, resulting in an internal fragment of 110 bp. Multiplex RT-PCR conditions were one cycle of 48 °C for 45 min, one cycle of 94 °C for 2 min and 40 cycles of 30 s at 94 °C, 1 min at 60 °C and 2 min at 68 °C, completed by a final cycle of 7 min at 68 °C.


    RESULTS AND DISCUSSION
 TOP
 INTRODUCTION
 METHODS
 RESULTS AND DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
The porA gene was amplified and sequenced from 47 of the 50 strains analysed (Table 1). The majority of isolates were not recognized by the subtyping panel as a result of non-synonymous base changes in the variable regions of the porA gene. Among strains from which the porA gene could be amplified, only three VR1/VR2 combinations had both epitopes identical to the corresponding mAb, while the rest had a variant of either VR1 of VR2 or both. Another possible reason for mAb subtyping failure may be the limited accessibility of the mAbs to the corresponding epitopes because of a large amount of capsular polysaccharide or lipopolysaccharide masking the PorA VR epitopes, as other authors have suggested previously (Sacchi et al., 2000). This possibility could explain the lack of recognition of epitopes identical to their prototype mAbs. Finally, lack of expression remained another important explanation for some cases of serotyping failure. It has been described previously that meningococci can down- or upregulate expression of the porA gene by changes in the number of G residues immediately preceding the –10 TATAAT box (van der Ende et al., 1995; Arhin et al., 1997; Sawaya et al., 1999). In this study, strains with a polyG tract ranging between 9 and 12 guanidine residues were found (Table 2). SDS-PAGE analysis showed the presence of PorA in all strains with a polyG tract ranging between 10 and 12 nt. Only one exception was found for a strain showing nine nucleotide residues in the –10 –35 region. In this isolate, SDS-PAGE detected no PorA. However, analysis of total RNA by RT-PCR showed that porA mRNA transcript was present, although its expression was lower than that found for other strains analysed that showed 10 or more nt residues.


View this table:
[in this window]
[in a new window]
 
Table 1. Distribution of PorA types among N. meningitidis strains VR1 and VR2 columns correspond to the nomenclature for particular variant types of variable regions 1 and 2 of the PorA protein. NT, Non-typable strains.
 

View this table:
[in this window]
[in a new window]
 
Table 2. Alterations found in the promoter region of the porA gene among NST N. meningitidis strains The putative –35 and –10 domains are underlined and the polyG tract is in bold.
 

In relation to the replacement of a guanidine residue by an adenine residue in the polyG tract, there are two contradictory hypotheses, Sawaya et al. (1999), by in vitro mutagenesis experiments, suggested that the replacement of guanidine by adenine residues decreased the promoter activity. On the other hand, van der Ende et al. (1995) suggested that substitutions in the polyG tract increased levels of PorA expression in these strains compared with others that presented identical number of residues in the polyG tract.

In our study, seven strains had mutations in the porA promoter spacer, replacing one or two residues in the homopolymeric tract of guanidine residues with adenine (Table 2). In our hands, in strains showing 10 nt residues in the polyG tract, replacing one or two residues of guanidine with adenine did not result in a clear difference in PorA expression by SDS-PAGE. For these cases, further analysis of the porA mRNA level by quantitative RT-PCR should be performed.

As well as variations in the porA promoter region, other types of phase variations affecting the coding region of the porA gene have been described (van der Ende et al., 1995). We found four subtypable strains corresponding to the P1.5, 2–1 antigenic combination by PorA sequencing, with no PorA expression by SDS-PAGE analysis. Two of these strains revealed a premature stop codon before the variable region VR1 caused by a single base-pair substitution (C->T) at position 109 of the porA coding region (GenBank accession no. AY319969). The other two present eight adenine residues in the homopolymeric tract of adenine in the coding region of porA, producing a DNA strand-slippage mechanism and PorA phase variation. SDS-PAGE and Western blotting using the correspondent mAbs confirmed the absence of PorA in these strains.

Finally, we describe the appearance of three NST strains by PorA typing. In these isolates, the PorA protein could not be amplified by PCR using any set of primers, and SDS-PAGE analysis did not detect PorA. Moreover, RT-PCR confirmed no porA mRNA transcript was present, suggesting that the porA gene in these strains was deleted, as other authors have suggested previously (van der Ende et al., 1999).

All these mechanisms have important implications for epidemiological analysis and vaccine design and demonstrate the need for genetic characterization, rather than phenotypic characterization using mAbs, for the identification of meningococcal strains. Moreover, the magnitude of microevolutionary mechanisms in meningococci and the remarkable genetic plasticity of these bacteria are important aspects to be considered in relation to PorA vaccine development and its potential efficacy.


    ACKNOWLEDGEMENTS
 TOP
 INTRODUCTION
 METHODS
 RESULTS AND DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 
B. A. and R. A. hold post-doctoral and pre-doctoral fellowships from Instituto de Salud Carlos III, respectively. Two pre-doctoral fellowships from Wyeth Farma supported C. S. and R. E. M. J. U. holds a pre-doctoral fellowship from FIS-02/9260. PorA type designation was performed by Janet Suker from NIBSC (National Institute for Biological Standards and Control).


    REFERENCES
 TOP
 INTRODUCTION
 METHODS
 RESULTS AND DISCUSSION
 ACKNOWLEDGEMENTS
 REFERENCES
 

  • Arhin, F. F., Moreau, F., Coulton, J. W. & Mills, E. L. (1997). Subtyping of Neisseria meningitidis strains isolated in Quebec, Canada: correlation between deduced amino acid sequences and serosubtyping techniques. Can J Microbiol 43, 234–238.[Medline]

  • Cartwright, K., Morris, R., Rumke, H., Fox, A., Borrow, R., Begg, N., Richmond, P. & Poolman, J. (1999). Immunogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17, 2612–2619.[CrossRef][Medline]

  • Crowe, B. A., Wall, R. A., Kusecek, B. & 7 other authors (1989). Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa. J Infect Dis 159, 686–700.[Medline]

  • Deghmane, A. E., Giorgini, D., Larribe, M., Alonso, J. M. & Taha, M. K. (2002). Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol 43, 1555–1564.[CrossRef][Medline]

  • de Kleijn, E. D., de Groot, R., Labadie, J. and 9 other authors (2000). Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18, 1456–1466.[CrossRef][Medline]

  • Feavers, I. M. & Maiden, M. C. J. (1998). A gonococcal porA pseudogene: implications for understanding the evolution and pathogenicity of Neisseria gonorrhoeae. Mol Microbiol 30, 647–656.[CrossRef][Medline]

  • Guiver, M. & Borrow, R. (2001). PCR diagnosis. In Meningococcal Disease: Methods and Protocols, pp. 23–39. Edited by A. J. Pollard & M. C. J. Maiden. Totowa, NJ: Humana Press.

  • Hopman, C. T. P., Dankert, J. & van Putten, J. P. M. (1994). Variable expression of the class 1 protein of Neisseria meningitidis. In Pathology and Immunobiology of Neisseriaceae, pp. 513–517. Edited by C. J. Conde-Glez, S. Morse, P. Rice, F. Sparling & E. Calderon. Cuernavaca, Mexico: Instituto Nacional de Salud Pública.

  • Longworth, E., Borrow, R., Goldblatt, D., Balmer, P., Dawson, M., Andrews, N., Miller, E. & Cartwright, K. (2002). Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20, 2592–2596.[CrossRef][Medline]

  • Martin, S., Sadler, F., Borrow, R., Dawson, M., Fox, A. & Cartwright, K. (2001). IgG antibody subclass responses determined by immunoblot in infants’ sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine. Vaccine 14, 4404–4408.

  • Newcombe, J., Cartwright, K., Dyer, S. & McFadden, J. (1998). Naturally occurring insertional inactivation of the porA gene of Neisseria meningitidis by integration of IS1301. Mol Microbiol 30, 453–454.[CrossRef][Medline]

  • Peeters, C. C., Rumke, H. C., Sundermann, L. C., Rouppe van der Voort, E. M., Meulenbelt, J., Schuller, M., Kuipers, A. J., van de Ley, P. & Poolman, J. T. (1996). Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14, 1009–1015.[CrossRef][Medline]

  • Rosenqvist, E., Hoiby, E. A., Wedege, E., Bryn, K., Kolberg, J., Klem, A., Ronnild, E., Bjune, G. & Nokleby, H. (1995). Human antibody response to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63, 4642–4652.[Abstract]

  • Sacchi, C. T., Whitney, A. M., Popovic, T. & 7 other authors (2000). Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States 1992–1998. J Infect Dis 182, 1169–1176.[CrossRef][Medline]

  • Saukkonen, K., Abdillahi, H., Poolman, J. T. & Leinonen, M. (1987). Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B : 15 : P1.16 in infant rat infection model: new prospects for vaccine development. Microb Pathog 3, 261–267.[CrossRef][Medline]

  • Saukkonen, K., Leinonen, M., Abdillahi, H. & Poolman, J. T. (1989). Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7, 325–328.[CrossRef][Medline]

  • Sawaya, R., Arhin, F. F., Moreau, F., Coulton, J. W. & Mills, E. L. (1999). Mutational analysis of the promoter region of the porA gene of Neisseria meningitidis. Gene 233, 49–57.[CrossRef][Medline]

  • Urwin, R. (2001). Nucleotide sequencing of antigen genes of Neisseria meningitidis. In Meningococcal Disease: Methods and Protocols, pp. 157–172. Edited by A. J. Pollard & M. C. J. Maiden. Totowa, NJ: Humana Press.

  • van der Ende, A., Hopman, C. T. P., Zaat, S., Oude Essink, B. B., Berkhout, B. & Dankert, J. (1995). Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the –10 and –35 regions of the promoter. J Bacteriol 177, 2475–2480.[Abstract/Free Full Text]

  • van der Ende, A., Hopman, C. T. P. & Dankert, J. (1999). Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis. Infect Immun 67, 2928–2934.[Abstract/Free Full Text]

  • van der Ende, A., Hopman, C. T. P. & Dankert, J. (2000). Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect Immun 68, 6685–6690.[Abstract/Free Full Text]

  • van der Ende, A., Hopman, C. T. P., Keijzers, W. C. M., Spanjaard, L., Lodder, E. B., van Keulen, P. H. J. & Dankert, J. (2003). Outbreak of meningococcal disease caused by PorA-deficient meningococci. J Infect Dis 187, 869–871.[CrossRef][Medline]

  • van der Voort, E. R., van Dijken, H., Kuipers, B., van der Biezen, J., van der Ley, P., Meylis, J., Claassen, I. & Poolman, J. (1997). Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect Immun 65, 5184–5190.[Abstract]

  • Vázquez, J. A., Marcos, C. & Berrón, S. (1994). Sero/subtyping of Neisseria meningitidis isolated from patients in Spain. Epidemiol Infect 113, 267–274.[Medline]




    This article has been cited by other articles:


    Home page
    J. Clin. Microbiol.Home page
    J. Castilla, J. A. Vazquez, C. Salcedo, M. Garcia Cenoz, J. J. Garcia Irure, L. Torroba, X. Beristain, R. Abad, and A. Barricarte
    B:2a:P1.5 Meningococcal Strains Likely Arisen from Capsular Switching Event Still Spreading in Spain
    J. Clin. Microbiol., February 1, 2009; 47(2): 463 - 465.
    [Abstract] [Full Text] [PDF]


    Home page
    CVIHome page
    R. Abad, B. Alcala, C. Salcedo, R. Enriquez, M. J. Uria, P. Diez, and J. A. Vazquez
    Sequencing of the porB Gene: a Step toward a True Characterization of Neisseria meningitidis
    Clin. Vaccine Immunol., October 1, 2006; 13(10): 1087 - 1091.
    [Abstract] [Full Text] [PDF]


    This Article
    Right arrow Abstract Freely available
    Right arrow Full Text (PDF)
    Right arrow Alert me when this article is cited
    Right arrow Alert me if a correction is posted
    Right arrow Citation Map
    Services
    Right arrow Email this article to a friend
    Right arrow Similar articles in this journal
    Right arrow Similar articles in PubMed
    Right arrow Alert me to new issues of the journal
    Right arrow Download to citation manager
    Right arrow reprints & permissions
    Citing Articles
    Right arrow Citing Articles via HighWire
    Right arrow Citing Articles via CrossRef
    Right arrow Citing Articles via Google Scholar
    Google Scholar
    Right arrow Articles by Alcalá, B.
    Right arrow Articles by Vázquez, J. A.
    Right arrow Search for Related Content
    PubMed
    Right arrow PubMed Citation
    Right arrow Articles by Alcalá, B.
    Right arrow Articles by Vázquez, J. A.
    Agricola
    Right arrow Articles by Alcalá, B.
    Right arrow Articles by Vázquez, J. A.


    HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
    INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS